Closing the hepatitis C treatment gap: United States strategies to improve retention in care
- PMID: 35545901
- PMCID: PMC9276641
- DOI: 10.1111/jvh.13685
Closing the hepatitis C treatment gap: United States strategies to improve retention in care
Abstract
The hepatitis C virus (HCV) treatment landscape is shifting given the advent of direct-acting antivirals and a global call to action by the World Health Organization. Eliminating HCV is now an issue of healthcare delivery. Treatment is limited by the complexity of the HCV care continuum, expensive therapy and competing health burdens experienced by an underserved HCV population. The objective of this literature review was to assess strategies to improve retention in HCV care, with particular focus on those implemented in the United States. We identified barriers in HCV care retention and propose solutions to increase HCV treatment delivery. The following recommendations are herein described: improving the cohesion of health services through localized care and integrated case management, expanding the supply of non-specialist HCV treatment providers, leveraging patient navigators and care coordinators, improving adherence through directly observed therapy and reducing cost barriers through value-based payment and pharmaceutical subscription models.
Keywords: care continuum; healthcare delivery; hepatitis C; retention; treatment.
© 2022 John Wiley & Sons Ltd.
Figures
Similar articles
-
Elimination of HCV in Russia: Barriers and Perspective.Viruses. 2022 Apr 11;14(4):790. doi: 10.3390/v14040790. Viruses. 2022. PMID: 35458520 Free PMC article. Review.
-
'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8. Addict Sci Clin Pract. 2021. PMID: 34384494 Free PMC article.
-
Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.Int J Drug Policy. 2023 Jan;111:103917. doi: 10.1016/j.drugpo.2022.103917. Epub 2022 Dec 19. Int J Drug Policy. 2023. PMID: 36542883
-
Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States.J Health Polit Policy Law. 2022 Dec 1;47(6):691-708. doi: 10.1215/03616878-10041121. J Health Polit Policy Law. 2022. PMID: 35867531 Free PMC article.
-
Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy.Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101564. doi: 10.1016/j.clinre.2020.11.001. Epub 2021 Mar 16. Clin Res Hepatol Gastroenterol. 2021. PMID: 33740477 Review.
Cited by
-
Current perspectives of viral hepatitis.World J Gastroenterol. 2024 May 14;30(18):2402-2417. doi: 10.3748/wjg.v30.i18.2402. World J Gastroenterol. 2024. PMID: 38764770 Free PMC article. Review.
-
Trends in Hepatitis C and Hepatitis B Deaths Identify Successes and Disparities, Alameda County, CA, 2005 - 2022.Gastroenterology Res. 2025 Jun 16;18(4):182-191. doi: 10.14740/gr2042. eCollection 2025 Aug. Gastroenterology Res. 2025. PMID: 40687325 Free PMC article.
-
Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs.Harm Reduct J. 2024 Aug 28;21(1):160. doi: 10.1186/s12954-024-01068-w. Harm Reduct J. 2024. PMID: 39198822 Free PMC article.
References
-
- World Health Organization (WHO). Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection.; 2018. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous